News

Overcoming data availability obstacles in the way of evidence-based toxicology

The availability of data from both preclinical and clinical studies of drugs is key to understanding the effectiveness and safety of any treatment before it is approved for use in patients. In a recent webinar our Director Dr Jan Turner, described why gaps in this data either through selective reporting or omission of significant data all together, can have profound effects on the decision-making of regulatory agencies and ultimately lead to unsafe drugs being placed on the market. Jan’s slides are available here.

Share
Follow Us

Latest Blog Posts

Presentation: Ending animal testing to advance human relevant research via New Approach Methodologies’

By Rebecca Ram I was pleased to be invited to give a presentation on the issues concerning use of animals in research at a recent workshop hosted by Advocates for Animals, the UK’s first legal organisation devoted to animal protection. The theme of the workshop was “Animal experiments; the law, the framework and the alternatives”. […]

Safer Medicines Trust at the 11th World Congress on Alternatives (WC11) 

Scientific consultant Rebecca Ram presented during a virtual session as part of the ‘YOU-WC11’ mentoring programme. The session theme was ‘Challenges and Opportunities for Expanding the 3Rs’’ and was particularly aimed at early career scientists. The session was further divided to discuss two topics; ‘Dropping an R: Is it Time to Retire Refinement?‘ featuring Charu Chandrasekera of […]